依洛尤单抗对青年初发急性心肌梗死患者降脂作用的疗效分析  

Lipid-lowering effect of Evolocumab in young patients with incipient acute myocardial infarction:an analysis on curative effect

作　　者：申晨[1] 王晓丽[1] 卢英霞[1] 赵秀峰[1] Shen Chen;Wang Xiaoli;Lu Yingxia;Zhao Xiufeng(Department of Cardiology,First Hospital of Handan City,Handan 056002,China;不详)

机构地区：[1]邯郸市第一医院心内科,邯郸056002

出　　处：《中国循证心血管医学杂志》2023年第7期805-807,817,共4页Chinese Journal of Evidence-Based Cardiovascular Medicine

基　　金：河北省卫生健康委科研计划项目(20200435)。

摘　　要：目的探讨依洛尤单抗对青年初发急性心肌梗死(AMI)合并高脂血症患者的调脂作用及安全性。方法选取2019年6月至2021年6月于邯郸市第一医院心血管内科治疗的低密度脂蛋白胆固醇(LDL-C)水平不达标的青年AMI患者,随机分为依洛尤单抗组和对照组,对照组仅实施调脂口服治疗,而依洛尤单抗组在对照组基础上加用皮下注射依洛尤单抗治疗(140 mg)。比较两组患者的LDL-C等血脂相关的指标由基线治疗第7 d治疗后的改变情况。结果本研究共入选患者86例,其中依洛尤单抗组44例,对照组42例。与对照组相比,治疗第7 d时,依洛尤单抗组LDL-C、非高密度脂蛋白胆固醇(Non-HDL-C)、总胆固醇(TC)、三酰甘油(TG)均明显降低,差异有统计学意义(P<0.05),LDL-C<1.4 mmol/L且较基线下降50%比例明显高于对照组(P<0.05),未发现实施依洛尤单抗治疗后出现肌酸激酶、肝酶等升高情况以及肾功能损伤的现象。结论与单独使用他汀类药物对比,依洛尤单抗可快速降低青年AMI患者的血脂水平,使LDL-C、Non-HDL-C达到指南推荐目标,且安全性良好。Objective To discuss the lipid-lowering effect and safety of Evolocumab in young patients with incipient acute myocardial infarction(AMI)complicated by hyperlipidemia.Methods Young AMI patients with non-compliance low-density lipoprotein-cholesterol(LDL-C)level were chosen from Department of Cardiology in the First Hospital of Handan City from June 2019 to June 2021.All patients were randomly divided into Evolocumab group and control group.The control group was given orally lipid-control drugs,and Evolocumab group was additionally given hypodermic injection of Evolocumab(140 mg).The changes of LDL-C and other related indexes were compared between 2 groups after baseline treatment for 7 d.Results There were totally 86 patients chosen and 44 in Evolocumab group and 42 in control group.On the 7th d,the levels of LDL-C,non-HDL-C,total cholesterol(TC)and triglyceride(TG)decreased significantly in Evolocumab group compared with control group(P<0.05).The percentage of patients with LDL-C<1.4 mmol/L and LDL-C decreased by 50%compared with baseline was significantly higher in Evolocumab group than that in control group(P<0.05).The increases of creatine kinase(CK)and hepatic enzymes and kidney function injury were not observed after Evolocumab treatment.Conclusion Evolocumab,compared with statins,can rapidly reduce blood fat level and improve levels of LDL-C and non-HDL-C to compliant the target with higher safety in young patients with AMI.

关 键 词：急性心肌梗死 青年 依洛尤单抗 低密度脂蛋白胆固醇 

分 类 号：R542.22[医药卫生—心血管疾病]